New structural and biochemical analyses of the hepatitis C virus E2 glycoprotein show that germline-reverted broadly neutralizing antibodies recognize the same conserved epitope as their mature counterparts, guiding engineered immunogen designs and exposing a key constraint in germline-targeting vaccine strategies.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.